Endocyte, Inc. (NASDAQ:ECYT) insider Philip S. Low acquired 5,600 shares of the stock in a transaction that occurred on Monday, November 13th. The shares were bought at an average cost of $4.84 per share, for a total transaction of $27,104.00. Following the completion of the transaction, the insider now directly owns 283,005 shares of the company’s stock, valued at approximately $1,369,744.20. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Shares of Endocyte, Inc. (NASDAQ ECYT) traded down $0.73 on Tuesday, reaching $4.60. 1,283,500 shares of the company were exchanged, compared to its average volume of 1,217,522. Endocyte, Inc. has a 52-week low of $1.17 and a 52-week high of $6.55.

Endocyte (NASDAQ:ECYT) last posted its earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.20). The business had revenue of $0.03 million during the quarter. Endocyte had a negative net margin of 82,235.72% and a negative return on equity of 38.91%. The firm’s revenue was up .0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.21) EPS. equities analysts anticipate that Endocyte, Inc. will post -1.24 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/14/philip-s-low-purchases-5600-shares-of-endocyte-inc-ecyt-stock.html.

ECYT has been the topic of a number of research analyst reports. Zacks Investment Research downgraded shares of Endocyte from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. ValuEngine raised shares of Endocyte from a “strong sell” rating to a “sell” rating in a research report on Monday, October 2nd. Wedbush raised shares of Endocyte from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $2.00 to $7.00 in a research report on Tuesday, October 3rd. Finally, Cowen and Company reaffirmed a “hold” rating on shares of Endocyte in a research report on Monday, October 2nd.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. lifted its stake in Endocyte by 1,064.3% in the second quarter. Goldman Sachs Group Inc. now owns 430,994 shares of the biopharmaceutical company’s stock valued at $646,000 after acquiring an additional 393,975 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Endocyte by 34.1% in the second quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 25,003 shares during the last quarter. FMR LLC lifted its stake in Endocyte by 0.9% in the second quarter. FMR LLC now owns 3,540,203 shares of the biopharmaceutical company’s stock valued at $5,310,000 after acquiring an additional 31,168 shares during the last quarter. LMR Partners LLP acquired a new stake in Endocyte in the second quarter valued at approximately $196,000. Finally, Spark Investment Management LLC acquired a new stake in Endocyte in the second quarter valued at approximately $177,000. Hedge funds and other institutional investors own 25.47% of the company’s stock.

Endocyte Company Profile

Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.